In vivo matrix metalloproteinase-7 substrates identified in the left ventricle post-myocardial infarction using proteomics

Journal of Proteome Research

Volumn 9, Issue 5, 2010, Pages 2649-2657

  Chiao, Ying Ann ^a   Zamilpa, Rogelio ^a   Lopez, Elizabeth F ^a   Dai, Qiuxia ^a   Escobar, Gladys P ^a   Hakala, Kevin ^a   Weintraub, Susan T ^a   Lindsey, Merry L ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Cardiac remodeling; Mice; MMP 7; Myocardial infarction; Proteomics

Indexed keywords

FIBRONECTIN; MATRILYSIN; PEROXIREDOXIN; PEROXIREDOXIN 1; PEROXIREDOXIN 2; PEROXIREDOXIN 3; TENASCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE INFARCTION; HEART LEFT VENTRICLE POST MYOCARDIAL INFARCTION; IMMUNOBLOTTING; MALE; MASS SPECTROMETRY; MORPHOMETRICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; QUANTITATIVE ANALYSIS; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANIMALS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FIBRONECTINS; HEART VENTRICLES; IMMUNOBLOTTING; MALE; MASS SPECTROMETRY; MATRIX METALLOPROTEINASE 7; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYOCARDIAL INFARCTION; MYOCARDIUM; PEROXIREDOXINS; PROTEOMICS; TENASCIN; VENTRICULAR REMODELING;

MUS;

EID: 77952063828     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr100147r     Document Type: Article

References (29)

1. Crabbe, T.; Willenbrock, F.; Eaton, D.; Hynds, P.; Carne, A. F.; Murphy, G.; Docherty, A. J. Biochemical characterization of matrilysin. Activation conforms to the stepwise mechanisms proposed for other matrix metalloproteinases Biochemistry 1992, 31 (36) 8500-7
2. Gaire, M.; Magbanua, Z.; McDonnell, S.; McNeil, L.; Lovett, D. H.; Matrisian, L. M. Structure and expression of the human gene for the matrix metalloproteinase matrilysin J. Biol. Chem. 1994, 269 (3) 2032-40
3. Boixel, C.; Fontaine, V.; Rucker-Martin, C.; Milliez, P.; Louedec, L.; Michel, J. B.; Jacob, M. P.; Hatem, S. N. Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in the rat J. Am. Coll. Cardiol. 2003, 42 (2) 336-44
4. Furman, C.; Copin, C.; Kandoussi, M.; Davidson, R.; Moreau, M.; McTaggiart, F.; Chapman, M. J.; Fruchart, J.-C.; Rouis, M. Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability Atherosclerosis 2004, 174 (1) 93-8
5. Lindsey, M. L.; Escobar, G. P.; Mukherjee, R.; Goshorn, D. K.; Sheats, N. J.; Bruce, J. A.; Mains, I. M.; Hendrick, J. K.; Hewett, K. W.; Gourdie, R. G.; Matrisian, L. M.; Spinale, F. G. Matrix Metalloproteinase-7 Affects Connexin-43 Levels, Electrical Conduction, and Survival After Myocardial Infarction Circulation 2006, 113 (25) 2919-28
6. Agnihotri, R.; Crawford, H. C.; Haro, H.; Matrisian, L. M.; Havrda, M. C.; Liaw, L. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin) J. Biol. Chem. 2001, 276 (30) 28261-7
7. Siri, A.; Knauper, V.; Veirana, N.; Caocci, F.; Murphy, G.; Zardi, L. Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases J. Biol. Chem. 1995, 270 (15) 8650-4
8. von Bredow, D. C.; Nagle, R. B.; Bowden, G. T.; Cress, A. E. Degradation of fibronectin fibrils by matrilysin and characterization of the degradation products Exp. Cell Res. 1995, 221 (1) 83-91
9. Imai, K.; Yokohama, Y.; Nakanishi, I.; Ohuchi, E.; Fujii, Y.; Nakai, N.; Okada, Y. Matrix metalloproteinase 7 (matrilysin) from human rectal carcinoma cells. Activation of the precursor, interaction with other matrix metalloproteinases and enzymic properties J. Biol. Chem. 1995, 270 (12) 6691-7
10. Crabbe, T.; Smith, B.; OConnell, J.; Docherty, A. Human progelatinase A can be activated by matrilysin FEBS Lett. 1994, 345 (1) 14-6
11. Haro, H.; Crawford, H. C.; Fingleton, B.; Shinomiya, K.; Spengler, D. M.; Matrisian, L. M. Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption J. Clin. Invest. 2000, 105 (2) 143-50
12. Stenman, S.; von Smitten, K.; Vaheri, A. Fibronectin and atherosclerosis Acta Med. Scand. Suppl. 1980, 642, 165-70
13. Willems, I. E.; Arends, J. W.; Daemen, M. J. Tenascin and fibronectin expression in healing human myocardial scars J. Pathol. 1996, 179 (3) 321-5
14. Orem, C.; Celik, S.; Orem, A.; Calapoglu, M.; Erdol, C. Increased plasma fibronectin levels in patients with acute myocardial infarction complicated with left ventricular thrombus Thromb. Res. 2002, 105 (1) 37-41
15. Imanaka-Yoshida, K.; Hiroe, M.; Nishikawa, T.; Ishiyama, S.; Shimojo, T.; Ohta, Y.; Sakakura, T.; Yoshida, T. Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction Lab. Invest. 2001, 81 (7) 1015-24
16. Nishioka, T.; Onishi, K.; Shimojo, N.; Nagano, Y.; Matsusaka, H.; Ikeuchi, M.; Ide, T.; Tsutsui, H.; Hiroe, M.; Yoshida, T.; Imanaka-Yoshida, K., Tenascin-C may aggravate left ventricular remodeling and function after myocardial infarction in mice. Am. J. Physiol. Heart Circ. Physiol. 2010, 298 (3), H1072-8.
17. Rudolph-Owen, L. A.; Hulboy, D. L.; Wilson, C. L.; Mudgett, J.; Matrisian, L. M. Coordinate Expression of Matrix Metalloproteinase Family Members in the Uterus of Normal, Matrilysin-Deficient, and Stromelysin-1- Deficient Mice Endocrinology 1997, 138 (11) 4902-11
18. Stanton, L. W.; Garrard, L. J.; Damm, D.; Garrick, B. L.; Lam, A.; Kapoun, A. M.; Zheng, Q.; Protter, A. A.; Schreiner, G. F.; White, R. T. Altered Patterns of Gene Expression in Response to Myocardial Infarction Circ. Res. 2000, 86 (9) 939-45
19. McLennan, S. V.; Kelly, D. J.; Schache, M.; Waltham, M.; Dy, V.; Langham, R. G.; Yue, D. K.; Gilbert, R. E. Advanced glycation end products decrease mesangial cell MMP-7: a role in matrix accumulation in diabetic nephropathy Kidney Int. 2007, 72 (4) 481-8
20. Davis, G. E., Matricryptic sites control tissue injury responses in the cardiovascular system: Relationships to pattern recognition receptor regulated events. J. Mol. Cell Cardiol. 2010, 48 (3), 454-60.
21. Keeling, J.; Herrera, G. A. An in vitro model of light chain deposition disease Kidney Int. 2009, 75 (6) 634-45
22. Imanaka-Yoshida, K.; Matsumoto, K.; Hara, M.; Sakakura, T.; Yoshida, T. The dynamic expression of tenascin-C and tenascin-X during early heart development in the mouse Differentiation 2003, 71 (4-5) 291-8
23. Sato, A.; Aonuma, K.; Imanaka-Yoshida, K.; Yoshida, T.; Isobe, M.; Kawase, D.; Kinoshita, N.; Yazaki, Y.; Hiroe, M. Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction J. Am. Coll. Cardiol. 2006, 47 (11) 2319-25
24. von Bredow, D. C.; Cress, A. E.; Howard, E. W.; Bowden, G. T.; Nagle, R. B. Activation of gelatinase-tissue-inhibitors-of-metalloproteinase complexes by matrilysin Biochem. J. 1998, 331, 965-72
25. Opdenakker, G.; Van den Steen, P. E.; Van Damme, J. Gelatinase B: a tuner and amplifier of immune functions Trends Immunol. 2001, 22 (10) 571-9
26. Immenschuh, S.; Baumgart-Vogt, E. Peroxiredoxins, oxidative stress, and cell proliferation Antioxid. Redox Signal. 2005, 7 (5-6) 768-77
27. Matsushima, S.; Ide, T.; Yamato, M.; Matsusaka, H.; Hattori, F.; Ikeuchi, M.; Kubota, T.; Sunagawa, K.; Hasegawa, Y.; Kurihara, T.; Oikawa, S.; Kinugawa, S.; Tsutsui, H. Overexpression of Mitochondrial Peroxiredoxin-3 Prevents Left Ventricular Remodeling and Failure After Myocardial Infarction in Mice Circulation 2006, 113 (14) 1779-86 (Pubitemid 43958471)
28. Nagy, N.; Malik, G.; Fisher, A. B.; Das, D. K. Targeted disruption of peroxiredoxin 6 gene renders the heart vulnerable to ischemia-reperfusion injury Am. J. Physiol. Heart Circ. Physiol. 2006, 291 (6) H2636-40
29. Dozier, S.; Escobar, G. P.; Lindsey, M. L. Matrix metalloproteinase (MMP)-7 activates MMP-8 but not MMP-13 Med. Chem. 2006, 2 (5) 523-6